J G Kahn1. 1. Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Abstract
BACKGROUND: Although the targeting of human immunodeficiency virus (HIV) prevention to high-risk populations has been widely discussed, its benefits have not been quantified. METHODS: This analysis of cost-effectiveness combines an HIV epidemic model, target population scenarios, and data on the cost and impact of prevention. RESULTS: The number of HIV infections averted in 5 years with $1 million in annual prevention spending ranges from 164 in high-risk populations to 0.4 in very-low-risk populations. Fortyfold to two-hundredfold differences in prevention costs could equalize HIV infections averted. CONCLUSIONS: Targeting appears to provide substantial benefit and should be considered in allocation decisions about prevention.
BACKGROUND: Although the targeting of human immunodeficiency virus (HIV) prevention to high-risk populations has been widely discussed, its benefits have not been quantified. METHODS: This analysis of cost-effectiveness combines an HIV epidemic model, target population scenarios, and data on the cost and impact of prevention. RESULTS: The number of HIV infections averted in 5 years with $1 million in annual prevention spending ranges from 164 in high-risk populations to 0.4 in very-low-risk populations. Fortyfold to two-hundredfold differences in prevention costs could equalize HIV infections averted. CONCLUSIONS: Targeting appears to provide substantial benefit and should be considered in allocation decisions about prevention.
Authors: G F Lemp; A M Hirozawa; D Givertz; G N Nieri; L Anderson; M L Lindegren; R S Janssen; M Katz Journal: JAMA Date: 1994-08-10 Impact factor: 56.272
Authors: D C Des Jarlais; S R Friedman; J L Sotheran; J Wenston; M Marmor; S R Yancovitz; B Frank; S Beatrice; D Mildvan Journal: JAMA Date: 1994-01-12 Impact factor: 56.272
Authors: D C Des Jarlais; H Hagan; S R Friedman; P Friedmann; D Goldberg; M Frischer; S Green; K Tunving; B Ljungberg; A Wodak Journal: JAMA Date: 1995-10-18 Impact factor: 56.272
Authors: Sarah Polk; Jonathan M Ellen; Caroline Fichtenberg; Steven Huettner; Meredith Reilly; Jenita Parekh; Jacky M Jennings Journal: AIDS Behav Date: 2014-08
Authors: Joseph Kagaayi; Ronald H Gray; Christopher Whalen; Pingfu Fu; Duncan Neuhauser; Janet W McGrath; Nelson K Sewankambo; David Serwadda; Godfrey Kigozi; Fred Nalugoda; Steven J Reynolds; Maria J Wawer; Mendel E Singer Journal: PLoS One Date: 2014-04-04 Impact factor: 3.240